In a recent study published in Science Advances, researchers found a new method that can prevent blood clots, and thus more serious diseases like stroke without causing major bleeding.
The study is from Michigan Medicine. One author is Michael Holinstat, Ph.D.
In the study, the team delivered the new drug, which they call ML355, by combining it with synthetic high-density lipoprotein, or sHDL, for this proof-of-concept investigation.
First, they tested it in human blood, and then in mouse models. The combination allowed for more precision than most of the antithrombotics currently available.
They were able to potently and selectively target regions of inflammation and injury in the blood vessel in order to prevent blood clots and thrombosis from occurring.
The team says that it’s the only selective inhibitor to block the activation of 12-lipoxygenase in the human platelet and prevent blood clots from forming.
The millions of people with heart disease in the U.S. would benefit greatly from a lower-risk option to avoid thrombosis.
The team adds that this discovery was successfully translated from the identification of a critical target in the platelet regulating thrombosis to clinical trials, recently receiving orphan drug designation from the U.S. Food and Drug Administration for prophylactic treatment of heparin-induced thrombocytopenia (HIT).
The FDA approved the Investigational New Drug application, and ML355 will begin clinical trials for novel treatment of patients suspected of HIT in March.
If you care about blood clots and your health, please read studies about food high in vitamin K may benefit people with blood clots and findings of some people with gout may have high risk of blood clots.
For more information about blood clot prevention and treatment, please see recent studies about common testosterone supplements that may increase men’s risk of blood clots and results showing that inflammation may cause dangerous blood clots in veins.